Detailed instructions for Vigabatrin/vigabatrin

Vigabatrin/vigabatrin, trade name: Sabril, is an anti-epileptic drug with a unique mechanism and is an irreversible inhibitor of gamma-aminobutyric acid (GABA) transaminase. By inhibiting the degradation of GABA, it significantly increases the level of GABA in the brain, thus exerting a powerful central nervous system inhibitory effect. Vigabatrin is mainly used to treat patients who have poor response to traditional anti-epileptic drugs, including refractory complex focal epilepsy (CPS) and infantile spasms (IS). It has been widely included in individualized treatment plans for epilepsy in Europe, the United States and other countries.

In terms of indications, Vigabatrin has a clear positioning. It can be used as an auxiliary treatment for children and adults aged 2 years and above with refractory complex focal epilepsy, especially for patients who have insufficient response to various other anti-epileptic drugs. It should be emphasized that Vigabatrin is not recommended as an initial treatment drug and should only be considered when first-line regimens are ineffective. In addition, it is approved as a monotherapy for infants aged 1 month to 2 years old, targeting patients with infantile spasms (IS), especially in TSC (tuberous sclerosis complex)-related IS. In this age group, the use of medications needs to be carefully determined based on an assessment that the clinical benefits outweigh the potential risks of vision loss.

Regarding specific usage and dosage, Vigabatrin uses dual standards of weight and age to formulate individualized treatment doses. For adults (≥17 years) with refractory complex focal epilepsy, the recommended starting dose is 500 mg twice daily. Subsequently, based on clinical response and tolerance, the dose can be increased by 500 mg each time every week, with the total dose not exceeding 3000 mg/day (i.e. 1500 mg/time, twice daily). Dosage for children needs to be strictly based on body weight. For example, the recommended starting dose for children weighing 10–15kg is 175mg twice a day, and the maintenance dose can be adjusted to 525mg/time; for children weighing 25–60kg, the maintenance dose can be up to 1000mg twice a day. Children weighing more than 60kg should take the adult dose directly.

For the treatment of infantile spasms (IS), Vigabatrin uses a more conservative starting dose of 25 mg/kg twice daily, and allows dose escalation every three days until the maximum dose is 75 mg/kg/time. According to clinical observations, if no substantial improvement in efficacy is seen within 2–4 weeks after the start of treatment, discontinuation of treatment should be considered to reduce unnecessary exposure to adverse reactions.

It is worth noting that the clinical use of Vigabatrin is highly dependent on early evaluation of efficacy. If inIf no significant benefit is observed in patients with CPS within 3 months, or no significant improvement in children with IS within 2–4 weeks, the medication should be discontinued immediately. The reason is that long-term use of this product may cause severe retinal toxicity, manifested as permanent visual field loss. Although this adverse reaction does not occur in every patient, its irreversibility makes visual monitoring a core link in the use of this drug. In European and American countries, after the launch of Vigabatrin, patients are required to undergo regular visual field examinations before and during treatment. Especially after the cumulative dosage of medication increases, the risk will increase significantly.

In addition, Vigabatrin may also cause central nervous system side effects such as drowsiness, fatigue, depression, and individual cases have reported psychiatric symptoms such as agitation or hallucinations. Patients with renal insufficiency should use it with caution and consider appropriate dosage adjustments. This drug is mainly excreted by the kidneys, and its blood concentration is likely to accumulate in patients with reduced renal function.

Reference materials:https://www.sabril.net/